Effects of PBMT-sMF in Mechanically Ventilated Patients

Last updated: August 6, 2024
Sponsor: University of Nove de Julho
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lung Injury

Respiratory Failure

Treatment

Placebo PBMT-sMF

Active PBMT-sMF

Clinical Study ID

NCT06454006
6.738.501
  • Ages > 21
  • All Genders

Study Summary

The goal of this clinical trial is to evaluate the effectiveness of photobiomodulation therapy combined with static magnetic field (PBMT-sMF) in adult patients who require mechanical ventilation. The main questions it aims to answer are:

(i) Does PBMT-sMF lower the length of stay in the intensive care unit (ICU) for mechanically ventilated patients? (ii) Does PBMT-sMF increase the diaphragm thickness in mechanically ventilated patients in the ICU?

Researches will compare active PBMT-sMF plus standard of care to a placebo PBMT-sMF plus standard of care to see if active PBMT-sMF works to prevent or retard disuse atrophy of the diaphragm during mechanical ventilation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Legally authorized representative signed informed consent;

  • Male or female aged 21 years or older;

  • On mechanical ventilation through orotracheal intubation for no more than 72 hoursprior to study enrollment or pending mechanical ventilation through orotrachealintubation;

  • Predicted to remain on mechanical ventilation for at least 48 hours (≥48 hours) fromthe time of study enrollment

Exclusion

Exclusion Criteria:

  • Mechanical ventilation initiated longer than 72 hours prior to anticipatedenrollment;

  • Body Mass Index (BMI) > 40 kg/m²;

  • Fever of 100.4°C or higher;

  • Situated in the prone position for 24 hours or longer during mechanical ventilation;

  • Prognosis of mortality within 72 hours, per the patient's physician;

  • Hypersensitivity to light;

  • Use of non-invasive ventilation, Continuous Positive Airway Pressure (CPAP) and/orBilevel Positive Airway Pressure (BiPAP) device for ≥ 50% of the time over thepreceding 6 months;

  • Tracheostomy;

  • Any one or more of the following present on both sides of the neck (bilaterally) atthe intended treatment site(s): internal jugular (IJ) venous cannulation; incisions,significant bruising; burn(s); notable skin irritation/rash, or other skin conditionthat may place the subject at risk from harm from the device treatment;

  • Fracture, external or internal hemorrhage, or at risk of hemorrhage following acutetrauma or fracture, or known or potential acute occult bleeding (e.g., gastriculcer, intestine) in the intended treatment areas;

  • Metallic device implants or body penetrating metallic devices in the upper body/neckarea whose location may interfere with the study device treatment administration.E.g., extracorporeal membrane oxygenation (ECMO) cannula;

  • Non-removable electrical/electronic device in the upper body/neck area that mayinterfere with the study device treatment administration, e.g., -implanted pacemakeror cardiac defibrillator;

  • Cardiogenic or septic shock with ongoing severe hemodynamic instability (accordingto the American College of Chest Physicians definition (that cannot be stabilizedwithin the 48 hours enrollment period);

  • Conditions that may limit ultrasonographic assessment of diaphragmatic thickness,e.g., occluding chest drain, pleural effusion, pulmonary consolidation of the lowerlobe(s);

  • Current cancer of any type;

  • Pregnancy;

  • Any comorbidity, co-existing condition or illness, or other factor that in theopinion of the study investigator may render the subject unsuitable forparticipation in the study;

  • Admission to the ICU within the last 12 months due to respiratory distress/failure;

  • Two or more admissions to the ICU within the prior 12 months for any reason;

  • Current participation in another clinical study.

Study Design

Total Participants: 112
Treatment Group(s): 2
Primary Treatment: Placebo PBMT-sMF
Phase:
Study Start date:
July 31, 2024
Estimated Completion Date:
December 31, 2025

Study Description

To achieve the proposed objectives it will be performed a multi-center, randomized, triple-blinded (patients, therapists, outcome assessors), placebo-controlled trial, in patients who required mechanical ventilation.

One hundred and twelve patients will be randomly allocated to two treatment groups:

  1. Active treatment: Patients will receive treatment with the active PBMT-sMF combined with standard of care therapy for a mechanically ventilated patient in the ICU.

  2. Placebo treatment: Patients will receive treatment with the placebo PBMT-sMF combined with standard of care therapy for a mechanically ventilated patient in the ICU.

The randomization will occur immediately following patients qualification and prior to any additional study activities occurring.

The treatment administration protocol (28-day administration protocol) will comprise: 7-minute treatment administration per day on each consecutive day for four consecutive weeks, for a maximum of 28 consecutive treatments over 28 consecutive days, or until the day of the patient's successful weaning from mechanical ventilation, or until the day of the patient's death, whichever occurs first.

The data will be collected by a blinded assessor.

Due to the nature of the condition being evaluated in this study, the study assessment timeline is patient dependent and will therefore be unique to each patient.

The study will comprise:

  1. pre-treatment evaluation phase (before starting treatment);

  2. treatment administration phase (two assessments: after completion of 14 and 28 days of treatment);

  3. post-treatment evaluation phase (any patient who is not discharged from the hospital or who does not die during the treatment administration and evaluation phase will proceed to the post-treatment administration phase. The post-treatment phase will start on the day immediately following the patient's last day in the treatment administration evaluation phase. The post-treatment phase will end on the day that the patient is discharged from the hospital, or the day that the patient dies prior to discharge from the hospital, whichever occurs firs. Therefore, the duration of the post-treatment administration phase will vary by individual patient. During the post-treatment evaluation period, the following assessments will be recorded once every two weeks, as applicable, with the final post-treatment evaluation visit determined on an individual patient basis, up to 2 years).

P.S.:

  • For patients whose successful weaning from mechanical ventilation occurs prior to completion of the 28-day administration protocol, the endpoint assessment visit will occur on or after the day of successful weaning.

  • For patients who die before completion of the 28-day administration protocol, the endpoint assessment visit will include outcome measures recorded as close to the date of the patient's death as possible.

The investigators will analyze: 1) Length of stay in the ICU; 2) Diaphragm thickness; 3) Length of stay in the hospital following ICU discharge; 4) Length of time until weaning from mechanical ventilation; 5) Mechanical ventilation parameters: (i) Positive end-expiratory pressure levels (PEEP) and (ii) Fraction of inspired oxygen (FiO2); 6) Arterial blood gas analysis: (i) Arterial partial pressure of oxygen (PO2) and (ii)PO2/FiO2 ratio; 7) Vital signs: blood pressure, heart rate, SpO2, blood glucose, etc.; 8) Blood draw analysis: C-reactive protein (CRP); Tumor necrosis factor-alpha (TNF-α); Vitamin D; erythrocytes; hemoglobin; hematocrit; leucocytes; segmented neutrals; eosinophiles; basophiles; lymphocytes; monocytes; platelet count;8) Survival rate; 9) Local skin reactions; 10) Adverse events and serious adverse events.

The statistical analysis will follow the intention-to-treat principles.

Connect with a study center

  • Santa Casa de Misericórdia de Porto Alegre

    Porto Alegre, Rio Grande Do Sul 90035-074
    Brazil

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.